Mar. 19 at 12:35 AM
$BMEA The stock has reached its trendline, and its direction—whether it will reverse downward or bounce—will likely be determined by next week. If it rebounds, the second target would be a breakout above the 120-day moving average.
BMEA is a company with limited cash reserves. While a offering is expected after the next clinical data release, it is unlikely to happen immediately. If the company intended to raise funds at the current price, insiders would not have been buying shares late last year.
